NAYA Biosciences Inc. - NAYA Operating profit EBITDA
NAYA Biosciences is implementing the Flex-NK platform to activate immune cells against tumors. This EBITDA chart visualizes current cash flow, where the value of corresponds to the current metric. The asset's value is based on patents in the absence of market sales, while future success in antibody biosynthesis will provide the company with powerful scaling leverage.
NAYA Biosciences Inc. (NAYA) - metric breakdowns and financial figures
- current quotes and average value forecast:
- issuer market value details:
- book value of equity indicators:
- debt level and financial liquidity data:
Debt to Equity Ratio NAYA Biosciences|NAYA - Long-Term Debt to Capital|Short-Term Debt to Capital NAYA Biosciences Inc|NAYA - Company Total Debt|Debts to Book Value NAYA Biosciences|NAYA - Company Long-Term Debts|Company Short-Term Debts NAYA Biosciences|Intermediate Coverage Ratio nayabiosciences.com
- earnings and market ratios statistics:
NAYA - Net Profit|Expected Profit NAYA Biosciences|NAYA - P/E Multiple|Market Cap to Projected Earnings nayabiosciences.com|NAYA - Price/Earnings to Growth Ratio|Company Value to EBITDA NAYA Biosciences|NAYA - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters NAYA Biosciences|NAYA - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months nayabiosciences.com|NAYA - Earnings growth in current year|Consensus forecast of earnings per share growth for next year NAYA Biosciences
Fundamental company valuation:NAYA Biosciences
NAYA Biosciences is scaling its developments in gene modification for oncology and reproductive medicine, building long-term scientific capital. This trend in absolute profit from core operations measures the daily liquidity inflow net of financial expenses, allowing investors to promptly identify any degradation in the business's operational efficiency prior to the publication of official quarterly reports.
Who NAYA Biosciences competes with
ONC - Operating profit before deduction of amortization|HALO: Operating profit before deduction of amortization|RVMD - Operating profit EBITDA|Ascentage Pharma (AAPG) - Profit before payment of interest, taxes and amortization|CG Oncology Inc - Income before deduction of interest, taxes and amortization|URGN (UroGen) - Operating profit EBITDA|Profit before interest, taxes and amortization Bicara Corp BCAX|Profit before payment of interest, taxes and amortization Personalis, Inc. (PSNL)|erasca.com - Operating profit before amortization|Operating profit EBITDA DCTH (Delcath Systems)|Operating profit EBITDA Y-mAbs Therapeutics Inc YMAB|AURA: Operating profit before deduction of amortization|Profit before interest, taxes and amortization Candel Therapeutics|ARAY: Operating profit EBITDA|SELLAS Life Sciences Group (SLS) - Operating profit EBITDA|Operating profit before deduction of amortization ACTU|CTOR: Income before deduction of interest, taxes and amortization|Operating profit EBITDA HURA|Profit before payment of interest, taxes and amortization TARA (Protara Tx)|Operating profit EBITDA FATE (Fate Therapeutics, Inc.)|Operating income before deduction of amortization Aadi Bioscience, Inc. (WHWK)|TCRX - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Champions Oncology|xbiotech.com (XBIT) - Profit before payment of interest, taxes and amortization|CVM - Operating income before deduction of amortization|OSTX (OS Therapies Incorporated) - Operating profit EBITDA|Operating profit before deduction of amortization radiopharmtheranostics.com (RADX)|Operating profit EBITDA ARTV|Operating income before deduction of amortization adlainortye.com|Operating profit EBITDA VERU (Veru Pharma)|Tempest Therapeutics Corp (TPST) - Profit before interest, taxes and amortization|XLO - Profit before payment of interest, taxes and amortization|RENB (Renovaro Inc.) - Operating profit before amortization|MURA: Operating profit EBITDA|Operating profit before deduction of amortization Kairos Pharma|OKUR (OnKure Therapeutics, Inc.) - Operating profit EBITDA|Profit before interest, taxes and amortization CytoMed GDTC|Profit before payment of interest, taxes and amortization Curis, Inc. (CRIS)|Operating income before deduction of amortization apollomicsinc.com|Profit before payment of interest, taxes and amortization Tharimmune THAR|ADVB: Operating profit before amortization|Genprex, Inc - Operating profit EBITDA|CLDI - Operating profit EBITDA|SBFM (Sunshine Biopharma, Inc.) - Operating profit before deduction of amortization|Profit before interest, taxes and amortization Xenetic Biosciences, Inc. (XBIO)|SLRX (Salarius Pharmaceuticals, Inc.) - Operating profit EBITDA|Operating profit EBITDA Purple Biotech Ltd|Operating profit EBITDA AONC|Operating profit before deduction of amortization BeiGene Ltd BGNE|Operating profit EBITDA CKPT (Checkpoint Therapeutics)|Operating profit EBITDA elevationoncology.com ELEV|ICAD - Profit before payment of interest, taxes and amortization|IKNA (Ikena Oncology, Inc.) - Operating profit before amortization|NTBL: Operating profit EBITDA|Operating profit before deduction of amortization Viracta Therapeutics, Inc.|MOR (MorphoSys AG) - Operating profit EBITDA|Profit before interest, taxes and amortization ascentage.com AAPGV
